The same underlying pathological process can result in a different constellation of symptoms and therefore result in a range of eventual diagnoses. For instance, the inability to properly metabolize vitamin B12 would affect each individual differently to some respect. I think this is what might be involved with KIR4.1, which is highly expressed in astrocytes.
In the following study the researchers concluded that the damage caused by a vitamin B12 deficiency is manifested as an increase in the number of cells positive for glial fibrillary acidic protein (a protein released by astrocytes during pathological processes in the central nervous system).
Prog Neurobiol. 2009 Jul;88(3):203-20. doi: 10.1016/j.pneurobio.2009.04.004. Epub 2009 Apr 24.
The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency.
“Glial cells, myelin and the interstitium are the structures of the mammalian central nervous system (CNS) mainly affected by vitamin B(12) (cobalamin, Cbl) deficiency. Most of the response to the damage caused by Cbl deficiency seems to come from astrocytes and microglia, and is manifested as an increase in the number of cells positive for glial fibrillary acidic protein…”
Researchers in the following study concluded that patients with MS had increased levels of glial fibrillary acidic protein (GFAP) and that GFAP levels correlated with neurological disablility and disease progression.
J Neurol. 2011 May;258(5):882-8. doi: 10.1007/s00415-010-5863-2. Epub 2011 Jan 1.
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J.
“The major intermediate cytoskeletal protein of astrocytes, glial fibrillary acidic protein (GFAP)…may…be released into the cerebrospinal fluid (CSF) during pathological processes in the central nervous system (CNS)…MS patients had increased GFAP levels compared with controls…and GFAP levels correlated with neurological disability…and disease progression…GFAP level at the first examination had predictive value for neurological disability 8-10 years later…GFAP, a marker for astrogliosis, is a potential biomarker for MS progression and may have a role in clinical trials for assessing the impact of therapies on MS progression.”
The lack of the enzymes DNase 1 and protease would lead not only to an inflammatory immune response, which would explain the activation of the dendritic cells and the involvement of proinflammatory cytokines, but it would also lead to many other consequences that would be seperate from the immune response (such as the inability to metabolize essential amino acids and vitamin B12), and this would be unique for each individual, even though the underlying pathological process would be the same.